AMRI's business risk profile 'weak,' says S&P

By Dan Stanton

- Last updated on GMT

Albany, New York-headquartered CDMO AMRI
Albany, New York-headquartered CDMO AMRI

Related tags Manufacturing

A Standards & Poor analyst has rated contract development and manufacturer AMRI as ‘stable,’ but says it lacks the scale and breadth of offerings of its competitors in the CDMO industry.

S&P assigned a ‘stable’ ratings outlook to Albany Molecular Research Inc. (AMRI) on the back of the recent acquisition of Valladolid, Spain-based firm Gadea Pharmaceutical Group​, which it believes the firm will smoothly integrate.

But while the $174m (€160m) deal expands AMRI’s active pharmaceutical ingredient (API) and drug manufacturing capabilities and capacity, as well as geographic presence, analyst Arthur Wong believes the firm is still in a precarious position compared to others in the third-party drug discovery, development, and manufacturing industry.

“We view AMRI's business risk profile as 'weak,' given that it competes in a niche industry and against larger players with greater size, scale, and breadth of offerings, partially offset by the company's focus on more advanced manufacturing processes,”​ he said in a note.

But AMRI is also bolstered by its discovery and development services (DDS), the note continued, which allows the firm to enter into contracts with clients at an earlier part of a product lifecycle.

According to its 2014 annual report, AMRI’s revenues are made up of around 57 % API supply, 12% drug product manufacturing and 31% from DDS.

“Our rating outlook on AMRI is stable, reflecting our expectation that the company will grow revenues mid- to high-single-digit area, in line with the contract research and manufacturing industries,”​ the note continued, adding that it is unlikely to upgrade the company over the next year.

AMRI’s second quarter 2015 results are set to be released on August 4.

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

State-of-the-Art Virtual Pharma Factory Tour

State-of-the-Art Virtual Pharma Factory Tour

Content provided by METTLER TOLEDO | 04-May-2023 | Event Programme

Join METTLER TOLEDO’s weighing experts on a virtual tour of a state-of-the-art manufacturing facility. On the call, you'll be digitally transported...

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Access GMP process liquids

Access GMP process liquids

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 18-Apr-2023 | Product Brochure

Accelerate your development and manufacturing of life-changing medicines with a reliable supply of your critical GMP-manufactured process liquids. Gibco...

Related suppliers

Follow us

Products

View more

Webinars